Vorläuferläsionen Ovarialkarzinom: Implikationen für Diagnostik und Therapie

Über viele Jahrzehnte galt das ovarielle Deckepithel als Ursprungsort des Ovarialkarzinoms. Heute gehen wir davon aus, dass es die Tube ist, der in unserem Verständnis der Krankheitsentstehung und damit auch im Kontext präventiver Konzepte eine Schlüsselrolle zugesprochen werden muss. Mit diesem Artikel geben wir einen aktuellen Überblick zur Bedeutung und klinischen Relevanz potenzieller Vorläuferläsionen epithelialer ovarieller Neoplasien.

Schlüsselwörter

Vorläuferläsionen - Ovarialkarzinom - Borderlinetumoren - STIC - HGSOC - LGSOC

• Literatur

• 1 Colombo N, Sessa C, Du Bois A. et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Int J Gynecol Cancer 2019;
• 2 Kurman RJ, Shih IeM. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol 2011; 42: 918-931
• 3 de Leo A, Santini D, Ceccarelli C. et al. What Is new on ovarian carcinoma: integrated morphologic and molecular analysis following the new 2020 World Health Organization classification of female genital tumors. Diagnostics (Basel) 2021; 11: 697
• 4 Gynäkologische Onkologie. Wallwiener D, Grischke EM, Brucker SY, Taran F-A, Bastert G. 8. Stuttgart: Schattauer; 2017
• 5 AWMF, Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Diagnostik, Therapie und Nachsorge maligner Ovarialtumoren. Langversion 3.0 [AWMF-Registernummer: 032/035OL]. 2019 Accessed March 15, 2022 at: https://www.awmf.org/leitlinien/detail/ll/032–035OL.html
• 6 Nishida N, Murakami F, Higaki K. Detection of serous precursor lesions in resected fallopian tubes from patients with benign diseases and a relatively low risk for ovarian cancer. Pathology Int 2016; 66: 337-342
• 7 Visvanathan K, Shaw P, May BJ. et al. Fallopian tube lesions in women at high risk for ovarian cancer: A multicenter study. Cancer Prev Res (Phila) 2018; 11: 697-706
• 8 Shih IM, Wang Y, Wang TL. The origin of ovarian cancer species and precancerous landscape. Am J Pathol 2021; 191: 26-39
• 9 WHO Classification of Tumours Editorial Board. Female Genital Tumours. 5. Lyon (France): International Agency for Research on Cancer; 2020
• 10 Mehra K, Mehrad M, Chen E. et al. STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis. Front Biosci (Elite Ed) 2011; 3: 625-634
• 11 Leonhardt K, Einenkel J, Sohr S. et al. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary. Int J Gynecol Pathol 2011; 30: 417
• 12 Wu RC, Wang P, Lin SF. et al. Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions. J Pathol 2019; 248: 41-50
• 13 Fruscella E, Testa AC, Ferrandina G. et al. Ultrasound features of different histopathological subtypes of borderline ovarian tumors. Ultrasound Obstet Gynecol 2005; 26: 644-650
• 14 Timmerman D, Testa AC, Bourne T. et al. Simple ultrasound-based rules for the diagnosis of ovarian cancer. Ultrasound Obstet Gynecol 2008; 31: 681-690
• 15 Van Calster B, van Hoorde K, Froyman W. et al. Practical guidance for applying the ADNEX model from the IOTA group to discriminate between different subtypes of adnexal tumors. Facts Views Vis Obgyn 2015; 7: 32-41
• 16 Hauptmann S, Friedrich K, Redline R. et al. Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch 2017; 470: 125-142
• 17 Hada T, Miyamoto M, Ishibashi H. et al. Clear cell borderline tumor without fibromatous component: Pathological and literature review and report of two cases. Mol Clin Oncol 2021; 14: 75
• 18 So KA, Hong SR, Kim NR. et al. Association between atypical endometriosis and ovarian malignancies in the real world. J Ovarian Res 2021; 14: 110
• 19 McAlpine JN, Hanley GE, Woo MMM. et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol 2014; 210: 471.e1-471.e11
• 20 Sieh W, Salvador S, McGuire V. et al. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol 2013; 42: 579-589